CN117327715A - Bacopa monnieri P450 enzyme gene BmCYP068 and application thereof - Google Patents
Bacopa monnieri P450 enzyme gene BmCYP068 and application thereof Download PDFInfo
- Publication number
- CN117327715A CN117327715A CN202311077715.2A CN202311077715A CN117327715A CN 117327715 A CN117327715 A CN 117327715A CN 202311077715 A CN202311077715 A CN 202311077715A CN 117327715 A CN117327715 A CN 117327715A
- Authority
- CN
- China
- Prior art keywords
- bmcyp068
- dammarenediol
- bacopa monnieri
- enzyme gene
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015418 Bacopa monnieria Nutrition 0.000 title claims abstract description 61
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title claims abstract description 43
- 240000002999 Bacopa monnieri Species 0.000 title claims abstract 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 3
- 239000002773 nucleotide Substances 0.000 claims abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 3
- NLHQJXWYMZLQJY-TXNIMPHESA-N dammarenediol-II Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4CC[C@@H]3[C@]21C NLHQJXWYMZLQJY-TXNIMPHESA-N 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- NLHQJXWYMZLQJY-UHFFFAOYSA-N Dammarendiol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4CCC3C21C NLHQJXWYMZLQJY-UHFFFAOYSA-N 0.000 claims description 8
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 5
- 230000033444 hydroxylation Effects 0.000 claims description 4
- 238000005805 hydroxylation reaction Methods 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 101150053185 P450 gene Proteins 0.000 claims description 2
- 244000234609 Portulaca oleracea Species 0.000 claims 1
- 235000001855 Portulaca oleracea Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 16
- 241000295198 Bacopa Species 0.000 abstract description 11
- 108700005075 Regulator Genes Proteins 0.000 abstract description 3
- 125000000539 amino acid group Chemical group 0.000 abstract description 2
- 244000187129 Bacopa monnieria Species 0.000 description 35
- 238000001514 detection method Methods 0.000 description 28
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 239000007795 chemical reaction product Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 229930182493 triterpene saponin Natural products 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 150000008130 triterpenoid saponins Chemical class 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- NLHQJXWYMZLQJY-AYHBXSNGSA-N Dammarenediol-I Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4CC[C@@H]3[C@]21C NLHQJXWYMZLQJY-AYHBXSNGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000008866 Ziziphus nummularia Species 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 2
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002012 ayurvedic medicine Substances 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- ZYZJWAJOTPNVPI-ZVBSCDOUSA-N cucurbitane Chemical compound C([C@H]1[C@]2(C)CC[C@@H]([C@]2(CC[C@]11C)C)[C@H](C)CCCC(C)C)CC2[C@H]1CCCC2(C)C ZYZJWAJOTPNVPI-ZVBSCDOUSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940081807 super 2x Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- -1 triterpene compounds Chemical class 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- OOTXFYSZXCPMPG-BMYLZFHVSA-N ursane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5[C@H]4CC[C@@H]3[C@]21C OOTXFYSZXCPMPG-BMYLZFHVSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
- C12N9/0081—Cholesterol monooxygenase (cytochrome P 450scc)(1.14.15.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/06—Hydroxylating
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/15—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced iron-sulfur protein as one donor, and incorporation of one atom of oxygen (1.14.15)
- C12Y114/15006—Cholesterol monooxygenase (side-chain-cleaving) (1.14.15.6), i.e. cytochrome P450scc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/102—Plasmid DNA for yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/85—Saccharomyces
- C12R2001/865—Saccharomyces cerevisiae
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a Bacopa monnieri P450 enzyme geneBmCYP068And the application in preparing 23-OH-Dammarenediol II and 25-OH-Dammarenediol II, which belong to the biotechnology field. The Bacopa P450 enzyme geneBmCYP068The nucleotide sequence is shown as SEQ ID NO.1, and the full length of the sequence is 1554bp; the amino acid sequence of the encoded protein is shown as SEQ ID NO.2, and 518 amino acid residues are encoded. The invention relates to a Bacopa monnieri P450 enzyme geneBmCYP068Can be used as 23-OH-Dammarenediol II andthe biosynthesis regulatory gene of 25-OH-Dammarenediol II is applied to the preparation of the biosynthesis regulatory gene, has obvious application prospect and is easy to popularize and apply.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a Bacopa monnieri P450 enzyme gene BmCYP068 and application thereof in preparation of 23-OH-Dammarenediol II and 25-OH-Dammarenediol II.
Background
Bacopa monnieri (L.) Wettst is a plant of the genus Bacopa aubl of the family Scrophulariaceae, and is mainly distributed in tropical and subtropical areas, mostly in water, wetland, beach, etc., and is mainly distributed in Taiwan, fujian, guangdong, yunnan, etc. provinces in China. Bacopa monnieri is a herb which is a good herb for India traditional ayurvedic medicine, is recognized as a high-value medicinal plant for brain nourishing, and can improve memory and intelligence. The global different research groups explored the use of Bacopa monnieri for the treatment of dementia, amnesia, memory dysfunction, parkinson's disease, alzheimer's disease, seizures and schizophrenia. In addition to neuroprotection, bacopa monnieri has sedative, antibacterial, anti-inflammatory, anticonvulsant, anti-aging, bronchodilatory, anti-cancer, antidepressant, anti-emetic and anti-ulcer activity. These potential pharmacological activities of Bacopa monnieri have been reported to be closely related to its secondary metabolite dammarane type triterpene saponin.
The triterpene saponin in Bacopa monnieri has a wide variety of contents, and can be classified into dammarane type, cucurbitane type, lupeol type, ursane type, etc. according to the structure. Among them, dammarane-type triterpene saponins are the most common components, and these compounds are closely related to the potential pharmacological actions of plants. The compounds exist in a glycoside form, the parent nucleus structure of the compounds mainly comprises wild jujube sapogenin and pseudo wild jujube sapogenin, and the compounds are different in the variety of the types and the modes of the connected glycosyl.
The triterpene saponin in Bacopa monnieri has low content and complex structure, and a large amount of raw materials are required for extraction from plant materials. However, the existing resources of the Bacopa monnieri are mostly wild, the quantity is rare and the distribution is scattered, the separation cost is high, and the chemical synthesis difficulty is high, so that the application of the triterpenoid saponin in the Bacopa monnieri is limited. Thus, the production of monomeric compounds using synthetic biology methods is one of the most efficient and viable methods for achieving large-scale production of triterpenoid saponins in Bacopa monnieri in the future. However, the current research on Bacopa monnieri mainly focuses on the extraction and separation of compounds and the identification of pharmacological activity, and the molecular mechanism of the triterpene saponin synthesis is not clear. To obtain dammarane-type triterpene saponins in Bacopa monnieri by biosynthetic methods, the biosynthetic pathways of these compounds were first analyzed.
The identification of the biosynthetic enzymes of spinosa and pseudospinosa sapogenins as key intermediates of bacopa triterpenoid saponins is a major issue. However, to date, the functions of the enzymes responsible for the production of the spinjujube seed sapogenins and the pseudo-spinjujube seed sapogenins in the Bacopa monnieri have not been verified, and the promotion of the biosynthesis work of dammarane type triterpenoid saponins in the Bacopa monnieri is affected.
Disclosure of Invention
The invention aims to solve the defects of the prior art, and provides a Bacopa monnieri P450 enzyme gene BmCYP068 which can be used as a regulating gene for forming 23-OH-dammarenedio II and 25-OH-dammarenedio II in the biosynthesis of Bacopa monnieri triterpenoid saponin and applied to preparing the 23-OH-dammarenedio II and the 25-OH-dammarenedio II.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the first aspect of the invention provides a Bacopa monnieri P450 enzyme gene BmCYP068, the nucleotide sequence of the Bacopa monnieri P450 enzyme gene BmCYP068 is shown in SEQ ID NO.1, and the total length of the sequence is 1554bp.
The second aspect of the invention provides the Bacopa monnieri P450 enzyme gene BmCYP068 coded protein, the amino acid sequence of the coded protein is shown in SEQ ID NO.2, and 518 amino acid residues are coded.
In a third aspect, the invention provides a recombinant plasmid containing the Bacopa monnieri P450 enzyme gene BmCYP068.
Further, it is preferable that the Bacopa monnieri P450 enzyme gene BmCYP068 is subjected to homologous recombination with the Y33 vector to obtain a Y33-BmCYP068 recombinant plasmid.
The fourth aspect of the present invention provides a genetically engineered bacterium comprising the recombinant plasmid, or wherein the genome of the genetically engineered bacterium has the exogenous Bacopa monnieri P450 enzyme gene BmCYP068 integrated therein.
Further, it is preferable that the transgenic engineering bacteria are Saccharomyces cerevisiae Dammarenediol I I chassis cells.
In a fifth aspect, the present invention provides a Bacopa P450 enzyme BmCYP068 obtained by encoding the Bacopa P450 enzyme gene BmCYP068.
In a sixth aspect, the invention provides the use of the Bacopa monnieri P450 enzyme gene BmCYP068 in the preparation of 23-OH-dammarenedio II and 25-OH-dammarenedio II.
Further, it is preferable that Dammarenediol II produced by the chassis cells is used as a substrate, and 23-OH-Dammarenediol II and 25-OH-Dammarenediol II are produced by hydroxylation at the 23-position or 25-position of a side chain under the catalysis of the Bacopa P450 enzyme BmCYP068 obtained by encoding the Bacopa P450 enzyme gene BmCYP068.
The invention obtains target protein after expression in saccharomyces cerevisiae chassis cells through recombinant plasmid, and directly generates 23-OH-dammarenedio II and 25-OH-dammarenedio II through further catalyzing substrate dammarenedio II.
The Bacopa monnieri P450 enzyme gene BmCYP068 is identified from plants of Bacopa monnieri through transcriptome sequencing and bioinformatics technology, and is screened after a large number of experiments; is obtained by a method of artificial synthesis through codon optimization. The amplification primer of the Bacopa monnieri P450 enzyme gene BmCYP068 is as follows:
5'F：ATGGCAGTTAAATTGAGCAGC；(SEQ ID NO.3)
3'R：TTACAATTTGTGCAAAACCATAGAAGC。(SEQ ID NO.4)
in addition, when homologous recombination is performed with vector Y33, bmCYP068 gene needs to be amplified and recovered by using a primer with a homology wall as follows:
upstream homology arm primer: 5'F: cagtcgacctcgaatctaga ATGGCAGTTAAATTGAGCAGC; (SEQ ID NO. 5).
Downstream homology arm primer: 3' R:
ctaattacatgatgcggcccTTACAATTTGTGCAAAACCATAGAAGC(SEQ ID NO.6)。
the P450 enzyme gene BmCYP068 separated and identified from the Bacopa monnieri can be used as an important marker gene for molecular auxiliary breeding of the Bacopa monnieri, and can also be used as an important candidate gene for producing 23-OH-dammarenedio II, 25-OH-dammarenedio II and Bacopa monnieri saponin in yeast chassis cell construction.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a P450 enzyme gene BmCYP068 which can be used as biosynthesis regulatory genes of 23-OH-Dammarenediol II and 25-OH-Dammarenediol II and applied to preparation
23-OH-Dammarenediol II and 25-OH-Dammarenediol II.
(1) Along with the rapid development of bioinformatics technology, the excavation of key enzyme genes of the biosynthesis path of triterpene compounds is greatly promoted, and biosynthesis regulating genes of 23-OH-Dammarenediol II and 25-OH-Dammarenediol II, namely P450 enzyme genes BmCYP068, are first identified and successfully verified in the Bacopa monnieri, so that a novel biosynthesis method for producing 23-OH-Dammarenediol II and 25-OH-Dammarenediol II is developed. The invention obtains the target product by heterologously expressing protein in saccharomyces cerevisiae and carrying out catalysis, adopts in vivo biosynthesis to carry out directional production, and has the advantages of high yield and the like.
(2) The invention provides a recombinant plasmid and a genetic engineering bacterium containing the P450 enzyme gene BmCYP068, which lay a foundation for synthesizing 23-OH-dammarenedio II and 25-OH-dammarenedio II in a large amount by a biological engineering method, and further lay a foundation for constructing cell factory researches for producing 23-OH-dammarenedio II and 25-OH-dammarenedio II.
(3) The 23-OH-Dammarenediol II and 25-OH-Dammarenediol II are synthesized by heterologous organisms, so that the controllability is high, the requirement on raw material planting can be reduced, the yield of the produced product is high, and the separation and purification of the 23-OH-Dammarenediol II and 25-OH-Dammarenediol II in the later period are convenient; can also reduce the problems of difficult chemical synthesis, complex synthesis path and the like. The P450 enzyme gene BmCYP068 is used as a key gene for biosynthesis of 23-OH-Dammarenediol II and 25-OH-Dammarenediol II, and can also be used for breeding research of Bacopa monnieri plants.
Drawings
FIG. 1 is a schematic diagram of synthetic pathways deduced for 23-OH-Dammarenediol II and 25-OH-Dammarenediol II;
FIG. 2 is a schematic diagram of the construction of recombinant expression plasmid Y33-BmCYP 068;
fig. 3 shows the result of electrophoresis detection after recombination of the Bacopa monnieri P450 enzyme gene BmCYP068. Wherein M is nucleic acid Mar,1-6 are positive single colony detection results;
FIG. 4 shows the HPLC detection of the catalytic effect of the Bacopa P450 enzyme gene BmCYP068 on the substrate Dammarenediol II in yeast (DM+PPD standard: dammarenediol II standard and PPD standard off-peak time; DM chassis+Y33 empty: control group Y33 empty plasmid as positive control reaction result; DM chassis+BmCYP 068: bacopa P450 enzyme gene BmCYP068 in yeast catalytic substrate Dammarenediol II reaction result, products 1 and 2 off-peak time).
FIG. 5 is a characteristic peak ion diagram (theoretical molecular weight 460) of reaction product 1 as a result of LC-MS detection.
FIG. 6 is a characteristic peak ion diagram (theoretical molecular weight 460) of reaction product 2 as a result of LC-MS detection.
FIG. 7 shows the result of NMR measurement, NMR of reaction product 1 13 C spectrum.
FIG. 8 shows the result of NMR measurement, NMR of reaction product 1 1 H spectrum.
FIG. 9 shows the result of NMR detection, 1HMBC spectra of the reaction product.
FIG. 10 shows the HSQC spectrum of reaction product 1, as a result of NMR detection.
FIG. 11 is a COSY spectrum of reaction product 1, which shows the result of NMR detection
FIG. 12 shows the ROESY spectrum of reaction product 1, which is the result of NMR detection.
FIG. 13 shows the result of NMR measurement, 2NMR of the reaction product 13 C spectrum.
FIG. 14 shows the result of NMR measurement, NMR of reaction product 2 1 H spectrum.
FIG. 15 shows the HMBC spectra of reaction product 2 as a result of NMR detection.
FIG. 16 shows the HSQC spectrum of reaction product 2, as a result of NMR detection.
FIG. 17 is a COSY spectrum of reaction product 2, which shows the result of NMR detection
FIG. 18 shows the ROESY spectrum of reaction product 2 as a result of NMR detection.
Detailed Description
The present invention will be described in further detail with reference to examples.
It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention. The specific techniques or conditions are not identified in the examples and are performed according to techniques or conditions described in the literature in this field or according to the product specifications. The materials or equipment used are conventional products available from commercial sources, not identified to the manufacturer.
Example 1
Screening CYP candidate genes in sequencing annotation results based on basic functional annotation information of the unicorn transcriptome, taking Cytochrome P450 Monooxygenase (CYPs) identified in plants as a reference sequence, performing sequence local BLAST analysis, performing finishing analysis on the screening results, and finally screening 20 CYP genes. Wherein the functional annotation of BmCYP068 is cytochrome P450 monooxygenase, and finally, unigene nucleotide sequences are extracted from fasta files according to the corresponding ID numbers of the Unigenes for subsequent analysis. And then carrying out a series of works such as codon optimization, artificial synthesis, homologous recombination, yeast chassis cell in-vivo induced expression, yeast metabolite extraction, HPLC, LC-MS, NMR detection and the like, and finally identifying that the BmCYP068 gene can catalyze 23-or 25-position hydroxylation of a Dammarenediol II side chain to generate 23-OH-Dammarenediol II and 25-OH-Dammarenediol II (figure 1). The procedure for each stage of the synthesis of 23-OH-Dammarenediol II and 25-OH-Dammarenediol II is as follows (reagents, raw materials, instrumentation, etc. used in the following examples are all commercially available):
(1) Codon optimization and artificial synthesis of BmCYP068 gene
The gene BmCYP068 coded by the P450 synthase annotated from the transcriptome is artificially synthesized by a company after codon optimization.
(2) Construction and identification of Gene recombination vectors
A schematic diagram of homologous recombination is shown in FIG. 2. The vector Y33 was first linearized, a single cleavage with XbaI enzyme was performed to obtain a linearized vector, the cleavage system (50. Mu.L) was used to obtain 1. Mu.g of a circular Y33 vector, 10 XNEBuffer was used to make up for 50. Mu.L of the entire system, and the reaction mixture was incubated at 37℃for 15 minutes to obtain a linearized vector Y33. And (5) recycling the EasyPure Quick Gel Extraction Kit kit, measuring the concentration of the kit after recycling, and finally storing the kit in a refrigerator at the temperature of minus 20 ℃ for standby. During homologous recombination, assembling according to the operation instructions of the homologous recombinase kit, and then calculating the consumption of each component according to the concentrations of the inserted fragment and the carrier and the recombination instructions; finally, the components were added to the PCR reaction tube on ice as shown in Table 1. The Bacopa P450 enzyme gene BmCYP068 and the Y33 vector are subjected to homologous recombination to obtain a recombinant plasmid, which is named as Y33-BmCYP068. The recombinant plasmid is transformed into DH5 alpha escherichia coli, positive clones are selected for detection and sent to a company for sequencing, and the assembled electrophoresis detection result is shown in figure 3, so that the assembly is successful. The method comprises the following steps of:
table 1candidate Gene recombination reaction System Table 1Candidate genes Recombination System
Wherein x= (0.02×y33 base pair) ng/linearising Y33 concentration ng/μl; y= (0.02×y33 base pair) ng/BmCYP068 recovery concentration ng/μl;
(3) Recombinant plasmid extraction
10 mu L of positive monoclonal seed preservation solution detected by suction sequencing is placed in 6mL of LB liquid medium (100 mg/mL of Amp) and cultured overnight at 37 ℃ in a shaking table (220 r/min). Extracting plasmid according to the specification of plasmid DNA small-scale preparation kit centrifugal column (GenStar, shenzhen China), measuring its recovery concentration on NanoReady ultra-micro ultraviolet visible spectrophotometer, and storing in-20deg.C refrigerator.
(4) DM Yeast chassis cell competent preparation
Selecting a DM chassis cell strain on an SC-His-Leu plate, inoculating the DM chassis cell strain into 100mL of SC-His-Leu liquid culture medium, culturing at 30 ℃ and 220rpm until OD=0.8-0.9, separating by using a 50mL centrifuge tube, and collecting thalli at 5000g/5 min. The cells were washed twice with 25mL of sterilized water, the centrifugation step was repeated, and the washed cells were resuspended in 1mL of ddH o and transferred to a 1.5mL centrifuge tube at 13000rpm, and the cells were collected by centrifugation for 30 s. Resuspension with 600 μl dd water, split 100 μl per tube for transformation
(5) DM Yeast chassis cell transformation
Centrifuging for 20s in a palm centrifuge, discarding supernatant, adding a transformation system: PEG4000 (50%) 240. Mu.L, LAC (lithium acetate) 1.0mol 36. Mu.L, SSDNA (frog's fish essence) 2.0 ug/. Mu.L 10. Mu.L, and a total of 74. Mu.L of plasmid with fragment of interest (400 ng) and ddH O. The mixed body weight is resuspended at 30 ℃ and kept for 20min, and is thermally shocked at 42 ℃ for 40min, 200 mu L of bacteria liquid coated plate SC-His-Leu-Ura is taken and placed in a 30 ℃ incubator for 2-4 days in an inverted way, and positive clone strains are selected for verification.
(6) Positive strain clone selection
mu.L of ddH2O was added to each of the 0.2mL PCR tubes, and 4 single colonies each of the above cultures were picked; and (3) carrying out reaction at 95 ℃ for 10min in a PCR instrument for wall breaking treatment. The following reaction system was added to the PCR tube: super 2x Mix 12.5. Mu.L, sterilized water 10.5. Mu.L, universal forward primer (10 mM) 0.5. Mu.L, universal reverse primer (10 mM) 0.5. Mu.L, 1. Mu.L of monoclonal template in water. Wherein the universal primer for detection is designed by software (SnapGene 3.2.1), and the upstream primer for detection:
GATGCTTTCTTTTTCTCTTTTTTTACAGATC, downstream primer:
GCGTGAATGTAAGCGTGAC; the PCR amplification cycle parameters were: 3min at 95 ℃;95 ℃ 30s,55 ℃ 30s,72 ℃ 90s,35 cycles; 72 ℃ for 5min and 10 ℃ for 5min.
(7) Detection and sequencing
Taking 1.0 mu L of Loading buffer and adding 5 mu L of the PCR product, uniformly mixing, and detecting an amplification result by 1% agarose gel electrophoresis, wherein if the amplification result is similar to the size of the target fragment, the amplification result is a true positive yeast strain, and the conversion is successful. The bacterial liquid identified as positive clone is cultured for 1 day by using SC-His-Leu-Ura liquid culture medium and then is preserved. The method comprises the steps of adding 50% glycerol and bacterial liquid into a seed preservation tube according to a ratio of 1:1, fully and uniformly mixing, and then placing into an ultralow temperature refrigerator at-80 ℃ for preservation for standby.
(8) Yeast induced expression and detection
Selecting normal positive transformation strain, culturing in SC-His-Leu-Ura liquid culture medium (50 ml), shaking culturing at 30deg.C and 220rpm for 5 days, centrifuging at 8000rpm for 5min, collecting cells, and breaking cell wall with 2ml lysate (20% KOH,50% EtOH); extracting with n-hexane of the same volume for three times; the extract was dried by spin-drying with a spin-evaporator and dissolved in 3ml of chromatographic methanol. The extracted metabolites were analyzed by HPLC.
The HPLC detection conditions were as follows:
the instrument used for HPLC detection is Agilent high performance liquid chromatograph. The column was an Agilent EC-C18 column (4.6X100 mm,2.7 um), column temperature: 25 ℃; the mobile phase was determined as: water (a) -acetonitrile (B), gradient elution: 0-10 min, 70-75% B; 10-20 min, 75-85% of B; 20-22 min, 85-100% of B; 22-25 min,100% B; mobile phase a+b used in elution totals 100%; linear gradient elution is adopted; elution time: 25min; sample injection amount: 10. Mu.L; flow rate: 0.8ml/min; the detection wavelength is 203nm, and the detector is a diode array detector. The detection result is shown in fig. 5, which shows that the experimental sample has new products under the catalysis of the Bacopa monnieri P450 enzyme BmCYP068.
LC-MS detection conditions were as follows:
to further confirm the reaction products detected by HPLC, detection was performed using an Agilent 1290UPLC/6540Q-TOF liquid chromatography mass spectrometer (LC/MS/MS): mass spectrometry conditions: the ion source adopts a negative ion mode and voltage: 3500V; fragmentation voltage: 135V; taper hole voltage: 60V; radio frequency voltage: 750V, scan range: 100-1000m/z, scanning mode: and SRM. Chromatographic conditions: the column was an Agilent EC-C18 column (4.6X100 mm,2.7 um), column temperature: 25 ℃; the mobile phase was determined as: water (a) -acetonitrile (B), gradient elution: 0-10 min, 70-75% B; 10-20 min, 75-85% of B; 20-22 min, 85-100% of B; 22-25 min,100% B; mobile phase a+b used in elution totals 100%; linear gradient elution is adopted; elution time: 25min; sample injection amount: 10. Mu.L; flow rate: 0.8ml/min; the detection wavelength is 203nm, and the detector is a diode array detector. Data analysis was performed using MassHunter workstation (Agilent) software. The detection results are shown in FIGS. 5-6.
From the above assay, it was speculated that Dammarenediol II was hydroxylated at two sites, respectively, under catalysis of the bacopa P450 enzyme BmCYP068. To determine the hydroxylation site, we performed NMR measurements on compounds 1 and 2. NMR measurements were performed on a Bruker AV-800MHz spectrometer (Santa Clara, USA) and the results are shown in FIGS. 7-18. From analysis of the results, compound 1 was identified as 23-OH-Dammarenediol II and Compound 2 was identified as 25-OH-Dammarenediol II.
Claims (9)
1. Bacopa monnieri P450 enzyme geneBmCYP068Characterized in that the Bacopa monnieri P450 enzyme geneBmCYP068The nucleotide sequence is shown as SEQ ID NO. 1.
2. The Bacopa monnieri P450 enzyme gene of claim 1BmCYP068The coded protein is characterized in that the amino acid sequence of the coded protein is shown as SEQ ID NO. 2.
3. Comprising the Bacopa monnieri P450 enzyme gene of claim 1BmCYP068Is a recombinant plasmid of (a).
4. The gene according to claim 3, which contains a Bacopa monnieri P450 enzymeBmCYP068Is characterized in that the Bacopa monnieri P450 enzyme geneBmCYP068Homologous recombination with Y33 vector to obtain Y33-BmCYP068Recombinant plasmids.
5. A transgenic bacterium comprising the recombinant plasmid according to claim 3, or wherein the genome of the transgenic bacterium has incorporated therein an exogenous Bacopa monnieri P450 enzyme gene according to claim 1BmCYP068。
6. The genetically engineered bacterium of claim 5, wherein the genetically engineered bacterium is a Dammarenediol II saccharomyces cerevisiae chassis cell.
7. The Bacopa monnieri P450 enzyme gene of claim 1BmCYP068Encoding the obtained Bacopa monnieri P450 enzyme BmCYP068.
8. The Bacopa monnieri P450 enzyme gene of claim 1BmCYP068The application in the preparation of 23-OH-Dammarenediol II and 25-OH-Dammarenediol II.
9. The Bacopa monnieri P450 enzyme gene according to claim 8BmCYP068The use in the preparation of 23-OH-Dammarenediol II and 25-OH-Dammarenediol II, characterized in that: taking Dammarenediol II produced by chassis cells as a substrate, and using the Bacopa monnieri P450 enzyme geneBmCYP068Coding the resulting falseThe purslane P450 enzyme BmCYP068 is catalyzed to generate 23-OH-Dammarenediol II and 25-OH-Dammarenediol II through hydroxylation at the 23-position or the 25-position of a side chain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311077715.2A CN117327715B (en) | 2023-08-25 | 2023-08-25 | Bacopa monnieri P450 enzyme gene BmCYP068 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311077715.2A CN117327715B (en) | 2023-08-25 | 2023-08-25 | Bacopa monnieri P450 enzyme gene BmCYP068 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117327715A true CN117327715A (en) | 2024-01-02 |
| CN117327715B CN117327715B (en) | 2024-06-14 |
Family
ID=89274481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311077715.2A Active CN117327715B (en) | 2023-08-25 | 2023-08-25 | Bacopa monnieri P450 enzyme gene BmCYP068 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117327715B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021190632A1 (en) * | 2020-03-26 | 2021-09-30 | 浙江大学 | Hydroxylase gene and use thereof |
| CN114507646A (en) * | 2020-11-17 | 2022-05-17 | 中国科学院分子植物科学卓越创新中心 | Cytochrome P450 mutant protein and application thereof |
| CN115927405A (en) * | 2022-11-15 | 2023-04-07 | 湖北大学 | Gene sequence for coding P450 enzyme and cytochrome P450 reductase derived from fusarium graminearum and recombinant strain thereof |
| CN116004553A (en) * | 2022-08-02 | 2023-04-25 | 中国医学科学院药用植物研究所 | Gene participating in gynostemma pentaphylla saponin synthesis and encoding product and application thereof |
-
2023
- 2023-08-25 CN CN202311077715.2A patent/CN117327715B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021190632A1 (en) * | 2020-03-26 | 2021-09-30 | 浙江大学 | Hydroxylase gene and use thereof |
| CN114507646A (en) * | 2020-11-17 | 2022-05-17 | 中国科学院分子植物科学卓越创新中心 | Cytochrome P450 mutant protein and application thereof |
| CN116004553A (en) * | 2022-08-02 | 2023-04-25 | 中国医学科学院药用植物研究所 | Gene participating in gynostemma pentaphylla saponin synthesis and encoding product and application thereof |
| CN115927405A (en) * | 2022-11-15 | 2023-04-07 | 湖北大学 | Gene sequence for coding P450 enzyme and cytochrome P450 reductase derived from fusarium graminearum and recombinant strain thereof |
Non-Patent Citations (2)
| Title |
|---|
| JEENA等: "Characterization of MYB35 regulated methyl jasmonate and wound responsive Geraniol 10‑hydroxylase‑1 gene from Bacopa monnieri", PLANTA, vol. 253, 31 December 2021 (2021-12-31), pages 1 - 13 * |
| 张雪;王希付;赵荣华;俞捷;顾雯;付兴情;曹冠华;贺森;: "药用植物甾体皂苷生物合成途径研究进展", 中国实验方剂学杂志, no. 14, 31 December 2020 (2020-12-31), pages 232 - 241 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117327715B (en) | 2024-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Biosynthesis of a ganoderic acid in Saccharomyces cerevisiae by expressing a cytochrome P450 gene from Ganoderma lucidum | |
| CN111518817B (en) | Hemsleya amabilis triterpene synthetase HcOSC6 gene, engineering bacterium thereof and application thereof in preparation of cucurbitadienol | |
| CN108929884B (en) | Method for heterogeneously biosynthesizing ganoderic acid by synthetic biological means | |
| CN117327715B (en) | Bacopa monnieri P450 enzyme gene BmCYP068 and application thereof | |
| CN113604470B (en) | Recombinant yarrowia lipolytica T30pED for high yield of campesterol, construction method and application thereof | |
| CN116396876A (en) | Saccharomyces cerevisiae engineering bacteria for producing ginsenoside Rd and construction method thereof | |
| CN115896136A (en) | Cytochrome P450 gene related to hydroxylation of cucurbitadienol and encoding product thereof | |
| CN116042425A (en) | Yeast engineering bacteria for producing patchouli alcohol and application thereof | |
| CN113956990B (en) | Recombinant saccharomyces cerevisiae for producing dihydronilotinib as well as preparation method and application thereof | |
| CN106754448B (en) | Recombinant yeast strain and application thereof | |
| CN115161208A (en) | Saccharomyces cerevisiae gene engineering bacteria and application thereof in producing cucurbitacin intermediate | |
| CN116334106A (en) | Application of hemsleyadin cytochrome oxidase gene and transgenic engineering bacteria thereof in preparation of cucurbitacin intermediate | |
| CN113444737B (en) | Cytochrome P450 enzyme and application thereof in synthesis of ganoderma lucidum triterpenoid | |
| AU2020102973A4 (en) | Method for preparing asterric acid through microbial fermentation | |
| CN111363753B (en) | Method for the heterologous production of linear triterpenes | |
| CN112646834A (en) | Lupeol derivative and synthesis method and application thereof | |
| CN113045410A (en) | Bicyclic norditerpenoid compound and synthetic gene and preparation method thereof | |
| CN116515872B (en) | Cyclocarya paliurus Liu San terpene synthase CpalOSC gene and application thereof in preparation of beta-amyrin | |
| CN107903227B (en) | Succinic anhydride compound, gene and protein related to succinic anhydride compound and preparation method of succinic anhydride compound | |
| CN113402357A (en) | 5-12-5 tricyclic sesterterpene skeleton compounds and preparation thereof | |
| CN116515872A (en) | Cyclocarya paliurus Liu San terpene synthase CpalOSC2 gene and application thereof in preparation of beta-amyrin | |
| CN115772507B (en) | Application of cytochrome P450 enzyme in synthesis of ganoderma lucidum triterpene | |
| CN114196641B (en) | Steroid C14 alpha hydroxylase, expression vector, engineering bacteria and application thereof | |
| CN117683651B (en) | Genetically engineered bacterium and construction method and application thereof | |
| CN114806914B (en) | Yarrowia lipolytica capable of producing beta-carotene at high yield and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |